Peptide News Digest

#Eye-Health

2 stories

Research · View digest

Stanford Review of 29 Patients With Uveitis and Related Eye Inflammation Finds Disease Mostly Stable and GLP-1 Drugs Well Tolerated

Researchers at Stanford's Byers Eye Institute reported in the Journal of Ophthalmic Inflammation and Infection on October 24, 2026 a retrospective study of 49 eyes in 29 patients with noninfectious uveitis, scleritis, or retinal vasculitis who started a GLP-1 drug (semaglutide in 89.7%) for diabetes, obesity, or both. Nine eyes had active inflammation before treatment; active disease was seen in five of 43, five of 47, and one of 37 evaluable eyes at six months, one year, and three years, and nine of 14 patients on steroids tapered or stopped them over three years. Fifteen adverse events occurred in 11 patients, mostly stomach symptoms and worse blood sugar control, with one serious event; the authors say the design cannot show the drugs improved the eye disease.

Research · View digest

GLP-1 Users With Type 2 Diabetes Had Fewer Retinal Artery and Vein Blockages in a Cleveland Records Study

Researchers at Case Western Reserve University and the Cleveland Clinic's Cole Eye Institute reported in the Journal of VitreoRetinal Diseases on October 17, 2026 a records study of adults with type 2 diabetes and eye follow-up, matching GLP-1 users with users of other diabetes drugs (53,413 pairs at one year, 14,695 at five years). GLP-1 users had a lower risk of any retinal vascular occlusion, a blockage of the eye's blood vessels that can cause vision loss, at one year (hazard ratio 0.66), three years (0.71), and five years (0.79). The authors called for prospective trials, since the design cannot prove the drugs prevented the blockages.